Pipeline
Our R&D portfolio currently consists of:
- New Chemical Entities in various fields, such as neurology and analgesia.
- New Advanced Therapies for inherited metabolic disorders.
Our portfolio and continued commitment to R&D, together with our manufacturing capacity, have allowed us to receive an "Excellent" rating in Group A of the Spain's Profarma Plan (Plan to Promote Scientific Research, Technological Development and Innovation in the Pharmaceutical Industry) continuously since 1986.
ESTEVE is implementing various programs that are currently in diverse stages of research and development.
Small Molecule Gene therapy
Moderate-to-Severe Acute Pain
E-58425: a novel, first-in-class co-crystal of Celecoxib and Tramadol
December 2021 update:
- Approval status. Approved by the Food and Drug Administration (FDA) in the US.
- Dossier for marketing authorization submitted to the Spanish agency (AEMPS), Italian agency (AIFA) and Portuguese agency (Infarmed), through a decentralized process in which Spain acts as a reference member State.
Neuropathic Pain
E-52862: a novel, first-in-class NCE selective Sigma-1 antagonist
Mucopolysaccharidosis Type IIIA
EGT-101: a potential first-in-class AAV-9 gene therapy administered via a one-time intracerebroventricular injection into the cerebrospinal fluid
General information about Sanfilippo Syndrome Type A or mucopolysaccharidosis (MPS) IIIA.
See more 
Pain-Related Disorders (Undisclosed)
MUMO-1: a novel, first-in-class NCE with a multi-modal mechanism of action that includes Sigma-1 antagonism
Mucopolysaccharidosis Type IIIB
EGT-201: a potential first-in-class AAV-9 gene therapy
Mucopolysaccharidosis Type II
EGT-301: a potential first-in-class AAV-9 gene therapy
Undisclosed
MUMO-5: a novel, first-in-class NCE with multimodal mechanisms of action
Lysosomal Storage Disorder (Undisclosed)
A potential first-in-class gene therapy
Neurodegenerative Disorders (Undisclosed)
Unique Sigma-1 Platform of agonists and antagonists
Internal projects with public financing
The internal projects developed in collaboration with multiple centres were financed mainly with Esteve's own resources, to which some competitive public grants has been added. Esteve has neither requested nor has it ever received funding from patients' associations or private individuals.
E-52862 has received grants from the Spains's Ministry of Economy and Competitiveness, via the Centre for Industrial Technological Development (CDTI) for clinical validation in neuropathic pain, as well as the projects Multimodal-1, Multimodal-2, Multimodal-3, Multimodal-5 and Sigma-1 new indications, that have also been partially co-financed by the European Union via the European Regional Development Fund (ERDF).
Project E-58425 has received a grant by the Catalonia Trade & Investment Agency (ACC1Ó) of the Generalitat de Catalunya as part of the line of loans for industrial innovation and experimental development projects via the Catalan Institute of Finance (ICF).
The Sanfilippo project has received grants from the Spain's Ministry of Economy and Competitiveness and the Ministry of Health, Social Policy and Equality, in competitive calls for research projects, in which the project was recognized for its scientific excellence.
The Phenopain project (Development of In Vitro Phenotypic Models of Pain and its Application to the Screening of High Throughput Compounds) aims to generate in vitro translational models for application to drug discovery to predict the therapeutic profile of new drugs in pain.
Phenopain has received funding from the RETOS-COLABORACIÓN program of the Ministry of Economy and Competitiveness and has been co-financed by the European Union through the European Regional Development Fund (FEDER).
